Botwood Sells Shares of Syndax Pharmaceuticals, Inc. (SNDX)
Botwood, CMO of Syndax, sold shares worth over $566,000 in a planned transaction.
Key Points
- Botwood, Head of R&D and CMO at Syndax Pharmaceuticals, sold 31,235 shares for $566,602 on June 12, 2026.
- Syndax Pharmaceuticals, trading at $18.26, has a market cap of $1.62 billion and a 52-week range of $8.59 to $25.59.
- Analysts maintain a strong buy consensus with a mean target price of $39, highlighting positive sentiment.
On June 12, 2026, Nicholas A.J. Botwood, Head of R&D and Chief Medical Officer at Syndax Pharmaceuticals, Inc. (NasdaqGS: SNDX), sold 31,235 shares of the company. The shares were sold at an average price of $18.14, totaling approximately $566,602. This transaction was part of a planned sale.
Insider Buying and Selling at Syndax Pharmaceuticals, Inc.
Botwood's recent transactions include both buying and selling activities. On the same day, Botwood also acquired 31,235 shares at a price of $0.00 and $13.82 in separate buys, indicating strategic portfolio adjustments. On June 11, 2026, Botwood sold 34,280 shares at $18.00 and acquired 22,515 shares at $0.00 and $13.82.
Other Institutional Activity in Syndax Pharmaceuticals
Several institutional investors have been active in Syndax Pharmaceuticals. BlackRock, Inc. increased its holdings by 15,424 shares, ending with 8,254,426 shares worth about $192.8 million. Kynam Capital Management, LP maintained its position with 8,050,959 shares valued at $188.1 million. Goldman Sachs Group Inc. reduced its stake by 698,588 shares, holding 4,996,787 shares valued at $116.7 million. State Street Corp cut its position by 166,476 shares, holding 4,430,076 shares worth $103.5 million, while Bank of America Corp trimmed its stake by 460,910 shares to 4,249,836 shares valued at $99.3 million.
Syndax Pharmaceuticals Stock Snapshot
Shares of Syndax Pharmaceuticals traded near $18.26. The company has a market cap of about $1.62 billion and a forward P/E ratio of -33.50, reflecting its current lack of profitability. Syndax's stock has a 52-week low of $8.59 and a high of $25.59. The 50-day moving average is $20.93, and the 200-day moving average is $19.45. The firm's current ratio stands at 5.47, with a quick ratio of 4.90 and a debt-to-equity ratio of 829.75.
Analysts Set New Price Targets
On May 22, 2026, HC Wainwright & Co. reiterated its buy rating with a $40 price target. UBS maintained its buy rating with a $37 target on May 13, 2026. Barclays also maintained a buy rating with a $37 target on May 1, 2026. The consensus among analysts is a strong buy, with a mean target price of $39 based on 12 analyst opinions.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company based in New York, NY. It develops cancer therapies, including Revuforj for acute leukemia and Niktimvo for chronic graft-versus-host disease. The company is also working on treatments for idiopathic pulmonary fibrosis and metastatic colorectal cancer. Led by CEO Michael A. Metzger, Syndax employs 298 people.
Bottom Line
Botwood's insider sale at Syndax Pharmaceuticals is part of a planned transaction, reflecting routine portfolio management. Syndax's stock, trading around $18.26, shows volatility within its 52-week range. Analysts maintain a strong buy consensus, indicating confidence in the company's future prospects. As always, keep in mind that insider transactions are disclosed after the fact and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.